-
Article
Open AccessEvaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
The objective of this study was to evaluate the safety and tolerability of DS-1205c, an oral AXL-receptor inhibitor, in combination with osimertinib in metastatic or unresectable EFGR-mutant non-small cell lung c...
-
Article
Open AccessUnderstanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination
Safety and efficacy of vaccines against the SARS-CoV-2 coronavirus has been demonstrated in clinical trials and next by their real world use through the course of the ongoing COVID-19 pandemic. However, very r...
-
Article
Open AccessOff-season RSV epidemics in Australia after easing of COVID-19 restrictions
Human respiratory syncytial virus (RSV) is an important cause of acute respiratory infection with the most severe disease in the young and elderly. Non-pharmaceutical interventions and travel restrictions for ...
-
Article
Open AccessRevaccination with Bacille Calmette-Guérin (BCG) is associated with an increased risk of abscess and lymphadenopathy
The reported frequency and types of adverse events following initial vaccination and revaccination with Bacille Calmette-Guérin (BCG) varies worldwide. Using active surveillance in a randomised controlled tria...
-
Article
Open AccessThe cost of care for children hospitalised with Invasive Group A Streptococcal Disease in Australia
Invasive Group A Streptococcal (iGAS) disease exerts an important burden among Australian children. No Australian hospitalisation cost estimates for treating children with iGAS disease exist, so the financial ...